In the CLL group, no significant difference was observed in microbiome composition with respect to the treatment status, immunoglobulin replacement therapy, or genetic biomarkers such as IGHV mutation status or TP53 mutation (Table S1). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.